Disease · MONDO_0018646
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Varices | 15 of 76 | 5 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants With Treatment Failure | 30 of 76 | 19 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Deaths | 5 of 76 | 3 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation | 13 of 76 | 10 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Cholangiocarcinoma | 2 of 76 | 2 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Developed Cirrhosis | 6 of 76 | 4 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: deaths from any cause | 5 of 76 | 3 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: Number of Participants Who Have a Liver Transplantation | 11 of 76 | 5 of 74 | 150 | NCT00059202 | Trial comparisons |
| Ursodeoxycholic Acid vs Placebo: serious adverse events | 0 of 76 | 0 of 74 | 150 | NCT00059202 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: deaths from any cause | 0 of 14 | 0 of 20 | 34 | NCT01802073 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: serious adverse events | 1 of 14 | 0 of 20 | 34 | NCT01802073 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: Count of Participants With Elevated ALT and/or GGT at Baseline and With Clinically Significant Improvement at Month 3 | 10 of 10 | 8 of 10 | 20 | NCT01802073 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3 | 10 of 10 | 6 of 9 | 19 | NCT01802073 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: Count of Participants With Abnormal MRCP and/or Liver Biopsy at Baseline and With Clinically Significant Improvement at Year 1 | 10 of 10 | 4 of 9 | 19 | NCT01802073 | Trial comparisons |
| Oral Vancomycin-Children vs Oral Vancomycin-Adults: Count of Participants With Elevated Gamma-glutamyltransferase (GGT) at Baseline and With Clinically Significant Improvement at Month 3 | 8 of 8 | 6 of 9 | 17 | NCT01802073 | Trial comparisons |
Oral Vancomycin-Children vs Oral Vancomycin-Adults: Count of Participants With Abnormal Magnetic Resonance Cholangiopancreatography (MRCP) Imaging at Baseline and With Clinically Significant Improvement at Year 1 | 6 of 8 | 4 of 8 | 16 | NCT01802073 | Trial comparisons |
| DUR-928 10 mg vs DUR-928 50 mg: deaths from any cause | 0 of 3 | 0 of 2 | 5 | NCT03394781 | Trial comparisons |
| DUR-928 10 mg vs DUR-928 50 mg: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT03394781 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018646/comparisons